Author(s) :

Saanvi C. Vadlamudi.

Volume/Issue :

Abstract :

Heart failure following a myocardial infarction (MI) remains a major global health challenge. This is largely attributable to the adult human heart’s limited innate regenerative capacity, which results in ventricular fibrosis, remodeling, and the formation of scar tissue. Early clinical trials evaluating bone marrow-derived mononuclear cells (BMMNCs) and mesenchymal stromal cells (MSCs) demonstrated acceptable safety profiles. Still, they produced only modest improvements in cardiac function and failed to replicate the robust benefits observed in preclinical models. This review examines the biological and methodological barriers responsible for this translational gap. Biologically, therapeutic efficacy is limited by the hostile post-infarction environment, which is characterized by hypoxia, inflammation, and oxidative stress, all of which contribute to extensive donor cell death, poor cell retention, and inadequate electrical integration with host myocardium. Methodologically, progress is hindered by small clinical trial sizes with limited statistical power coupled with high heterogeneity in cell preparations, dosing, and delivery routes. Furthermore, the widespread reliance on surrogate imaging endpoints, particularly on the left ventricular ejection fraction (LVEF), rather than definitive clinical outcomes, such as mortality, heart-failure hospitalization, functional status, and quality of life, limits the interpretation of therapeutic efficacy. In response to these limitations, the field is shifting toward cell-free therapies utilizing extracellular vesicles and exosomes to deliver cardiovascular bioactive molecules, as well as direct cardiac reprogramming to convert resident scar-forming fibroblasts into functional cardiomyocytes. Successfully overcoming these translational barriers will require standardized trial designs, rigorous product characterization criteria, and greater emphasis on clinically meaningful endpoints.